Andy Smith
Andy Smith gives an analyst and investor’s view on life science companies. He has been the lead fund manager for four life science–specific funds, including 3i Bioscience, International Biotechnology and the AXA Framlington Biotech Fund, and was chief investment officer at Mannbio Invest. He was a global product manager at SmithKline Beecham Pharmaceuticals until 2000.
Andy joined the independent research house Equity Development in 2019 having previously been an analyst at Edison group and a Senior Principal in ICON PLC’s Commercialization, Pricing and Market Access consulting practice.